Management of Pigmented Villonodular Synovitis (PVNS): an Orthopedic Surgeon’s Perspective
- 4 June 2020
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 22 (6) , 1-6
Abstract
Purpose of Review Pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumor (TGCT) encompasses a wide spectrum of disease and is divided into localized and diffuse variants. Surgical resection remains the principal treatment for nearly all localized type disease and most diffuse type. Recent mechanistic understanding of the disease led to drug discovery that has opened new avenues for patients with recalcitrant disease. In this manuscript, we review the current treatment options for TGCT, presenting outcomes from traditional surgical approaches as well as those from nonsurgical approaches. Recent Findings Arthroscopic and/or open surgery remains the mainstay of treatment for TGCT for the vast majority of patients. While radiosynoviorthesis and external beam radiation have been used for recalcitrant disease, recent understanding of the colony stimulating factor 1 receptor (CSF1R) pathway and its paracrine and autocrine role in TGCT has led to the development of targeted inhibitors. Their optimal role and efficacy are unclear due to limited number of high-quality studies and contradictory results; however, recent and ongoing studies suggest there may be a role for their use, especially in diffuse and/or refractory disease. Summary Surgery remains the most common treatment for TGCT, however, there may be an increasing role for adjuvant therapies, including the new targeted agents. Weighing the side effects of these treatments against the symptomatic benefit on a patient-by-patient basis in this benign disease remains critical.Keywords
This publication has 22 references indexed in Scilit:
- Higher incidence rates than previously known in tenosynovial giant cell tumorsActa Orthopaedica, 2017
- UK guidelines for the management of soft tissue sarcomasClinical Sarcoma Research, 2016
- Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectivesEuropean Journal of Cancer, 2016
- The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the kneeThe Bone & Joint Journal, 2015
- Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitorsEuropean Journal of Cancer, 2015
- A comparison of open and arthroscopic surgery for treatment of diffuse pigmented villonodular synovitis of the kneeKnee Surgery, Sports Traumatology, Arthroscopy, 2014
- Does Combined Open and Arthroscopic Synovectomy for Diffuse PVNS of the Knee Improve Recurrence Rates?Clinical Orthopaedics and Related Research, 2013
- The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis)The Journal of Bone and Joint Surgery. British volume, 2012
- Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive SynovitidesAmerican Journal of Surgical Pathology, 2007
- A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cellsProceedings of the National Academy of Sciences, 2006